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ABSTRACT
Objective: Role of leptin resistance in correlation between obesity and asthma.
Methods: High-caloric diet was given for 8 weeks to induce obesity. Ovalbumin followed by aluminum hydroxide was given to induce asthma. The 
animal was treated with leptin analog (0.4 mg/kg, i.p. for 7 days) and leptin antagonist (3 mg/kg, p.o., for 7 days). Biochemical parameters such as 
serum leptin, ghrelin, and tumor necrosis factor alpha (TNF-α) and physical parameters such as tidal volume and airflow rate were estimated to 
confirm the state of asthma and obesity, respectively.
Results: It was found that leptin and ghrelin were elevated in obese and obese asthmatic condition, responsible for leptin resistance. Treatment with 
leptin analog and leptin antagonist significantly increases and decreases serum leptin levels, respectively. There was no significant change in TNF-α 
and ghrelin level after leptin analog treatment. The result of respiratory parameters improved with leptin analog. From our study, we found beneficial 
role of leptin analog in obese asthmatic condition.
Conclusion: Leptin is an alternative treatment approach to treat obese asthmatic condition.
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INTRODUCTION
Obesity is one of the inflammatory conditions characterized by fat 
deposition in the adipose tissue [1,2]. Obesity is linked with several 
disorders including cardiovascular diseases, certain types of cancer [3], 
and type-2 diabetes and it also raises the risk of pulmonary problems 
including asthma [4,5]. It is a strong risk factor for mortality in 
adulthood. The study revealed that overall 20% of males and 30% of 
females are obese worldwide [4]. The reason is due to rapid urbanization 
and westernization of countries. This leads to consumption of larger 
amounts of food with decreased physical activities, results in higher 
chances of obesity [5].
Asthma is chronic inflammatory respiratory disorder characterized 
by airway hyperresponsiveness that leads to recurrent episodes 
and reversible airflow obstruction [6]. Obesity has been significantly 
associated with asthma in both genders [7]. Studies indicated that 
obesity may increase asthma severity and reduce the efficacy of 
standard asthma medications [8]. Various clinical cohort studies 
showed that over 300,000 adults whose body mass index >25 were 
diagnosed with asthma [9].
It is well established that insulin, leptin, and ghrelin levels are 
significantly altered in obesity and asthma [10]. Leptin and ghrelin 
regulate satiety center by acting on brain centers. Both control the 
food intake through acting on neuropeptide Y pathway. Various studies 
showed that obesity is due to either leptin resistance or elevated 
serum level [3-5]. Clinical studies also revealed higher level of leptin in 
asthmatic patients [11].
Both asthma and obesity are chronic inflammatory conditions [9]. 
Leptin is an inflammatory hormone secreted from adipose tissue [12]. 
The obese state could lead to asthma in those without prior airway 
disease in a number of different ways. These include changes in lung 
structure and function related to diet and mechanics, oxidative stress 
signaling, cytokine derangement, and neuronal signaling pathways. 
Growing evidence also suggests that the pro-inflammatory effects of 
leptin may contribute to the higher incidence of asthma in the obese 
population [13,14].
At present, there are limited treatment options available for these two 
comorbid conditions. Even current treatments also have numerous 
side effects. Therefore, there is a need for identification of newer cost-
effective treatment approach for asthma with obesity. The present 
investigation was done to find possible role of leptin in pathogenesis of 
asthma with obesity. We investigated role of leptin through high-caloric 
diet-induced obesity in ovalbumin (OVA)-induced asthma in Swiss 
albino mice.
METHODS
Swiss albino mice of female sex weighing between 24±6 g were 
obtained from the central animal house of Faculty of Pharmacy, 
Dharmsinh Desai University, Nadiad. The animal studies were 
approved by the Institutional Ethics Committee (FOP/06/17), ratified 
by the purpose of control and supervision of experimental animals by 
Ministry of Environment and Forests, Government of India, New Delhi, 
India. Animals were naive to drug treatment and experimentation 
at the beginning of all studies. Animals were kept individually in 
polypropylene cages in an environmentally controlled room of the 
animal house and maintained at a temperature of 25±2°C with a 12 h 
dark and light cycle. 10 days of acclimatization were provided to animal. 
The animals were provided water and food ad libitum. Mice were fed 
with laboratory pellet chow diet or special high-caloric diet according 
to the protocol. Composition of experimental diet (gm/kg diet) was 
according to Soni et al. [7].
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Experimental design
A total of 60 mice were used and divided into 10 groups (n=6).
Group I: (Normal control mice) Animals were maintained on laboratory 
pellet chow diet and water ad libitum for 12 weeks. No treatment was 
given to these mice.
Group II: (Obese control mice) Animals were maintained on the high-
caloric diet for 8 weeks to induce obesity.
Group III: (Asthma control mice) Animals were maintained on 
laboratory pellet chow diet for up to 8 weeks, and then, induction phase 
of asthma was started. Mice were sensitized with OVA conjugated to 
aluminum hydroxide and challenged with saline to induce asthma. The 
induction with OVA was done on day 1–day 23 and challenge was given 
for every 7th day for 3 weeks.
Group IV: (Obese asthmatic control mice) Animals were given with high-
caloric diet control mice maintained for 8 weeks, and then, induction 
phase of asthma was started. Mice were sensitized with OVA conjugated 
to aluminum hydroxide and challenged with saline to induce asthma. 
The induction with OVA was done on day 1–day 23 and challenge was 
for every 7th day for 3 weeks.
Group V: (Leptin analog-treated obese mice) Animals were fed with 
high-caloric diet as mentioned in Group-II and these animals were 
treated with leptin analog (0.4 mg/kg, i.p. for 7 days) during the 
9th week of study.
Group VI: (Leptin analog-treated asthmatic mice) Animals were treated 
same as mentioned in Group-III and these animals were treated with 
leptin analog (0.4 mg/kg, i.p. for 7 days) during the 9th week of study.
Group VII: (Leptin analog-treated obese asthmatic mice) Animals were 
treated same as mentioned in Group-IV and these animals were treated 
with leptin analog (0.4 mg/kg, i. p. for 7 days) during the 12th week of 
study.
Group VIII: (Leptin antagonist-treated obese mice) Animals were fed 
with high-caloric diet as mentioned in Group-II and these animals were 
treated with leptin antagonist (3 mg/kg, p. o., for 7 days) during the 
9th week of study.
Group IX: (Leptin antagonist-treated asthmatic mice) Animals were 
treated same as mentioned in Group-III and these animals were treated 
with leptin antagonist (3 mg/kg, p. o., for 7 days) during the 9th week 
of study.
Group X: (Leptin antagonist-treated obese asthmatic mice) Animals 
were treated same as mentioned in Group-IV and these animals were 
treated with leptin antagonist (3 mg/kg, p. o., for 7 days) during the 
12th week of study.
At the end of experimental period, the animals were anesthetized 
with ketamine, following overnight fasting. Blood was drawn by retro-
orbital method. Serum was separated by centrifugation at 4000 rpm 
(revolution per minute). Serum levels of leptin, ghrelin, and tumor 
necrosis factor-α (TNF-α) were measured using standard ELISA kits. 
The serum samples were stored at −70°C until analysis.
Measurement of respiratory parameters
Tidal volume, respiratory rate, and airflow rate were measured for the 
assessment of asthmatic condition. Tidal volume is the volume of air 
inhaled or exhaled per breath during normal breath. The measurement 
of tidal volume was done with the help of respiratory volume transducer 
using student physiograph. The physiograph was calibrated with the 
help of 0.02 cc and 0.1 cc volume air supplier. The tidal volume was 
measured in terms of height of the response obtained. Then, the height 
was converted to volume [15].
Respiratory rate is the number of breath per unit time. The respiratory 
waves recorded for the tidal volume was counted for a period of 1 min 
and expressed as breaths per minute. Airflow rate is a volume of air 
inspired or expired per unit time during normal breathing [15]. It was 
calculated as follows:
Airflow rate=Respiratory rate*tidal volume.
Chemicals and diagnostic kits
Leptin analog (recombinant Mouse leptin - cyt-31), leptin antagonist 
(MBS 400080 Pegylated mouse super leptin antagonist - mutant 
D23/L39A/D40A/F414A), ELISA kit for leptin (ELM-leptin-1 Mouse 
leptin ELISA 1*96 well), ghrelin (EIAM-GHR-1 Mouse EIA 1*96 well), 
and TNF-α (ELM-TNF-α-1 mouse TNF-α ELISA 1*96 well) were 
purchased from Everon Life Sciences, New Delhi, India.
Statistical analysis
Statistical evaluation of analytical data was done by one-way analysis of 
variance followed by Tukey’s test using statistical software GraphPad 
Prism 3.0. Data were expressed as mean ± standard error of the mean 
and statistically significant was determined at p<0.05.
RESULTS
Endocrinological effect of leptin and leptin antagonist in the state of 
obese asthmatic condition was evaluated using various physical and 
biochemical parameters. The results of physical parameters are given 
in Table 1 while biochemical parameters represented by graphical 
presentation.
Effect of leptin analog and antagonist on body weight
Obesity was induced in normal mice by feeding hypercaloric diet for 
8 weeks. The mean body weight of the disease control animals was 
compared to the control animal. The mean body weight of leptin analog-
treated obese, asthmatic, and obese asthmatic group was compared to 
the obese, asthmatic, and obese asthmatic animal, respectively. Same 
was done for leptin antagonist-treated animals.
There was a significant (Group I, *p<0.05) increase in calorie intake per 
week among the high-caloric diet mice as compared to normal diet-
fed mice while in case of treatment with leptin and leptin antagonist, 
changes in caloric intake were observed when compared to standard 
disease control group (Table 1). There was significant decrease in 
caloric intake after leptin treatment when compared to disease control 
animal (Group II, III, and IV as @, #, and $p<0.05).
Effect of leptin analog and antagonist on respiratory parameters
The tidal volume and airflow rate were measured as respiratory 
parameters. It was observed that tidal volume and airflow rate of obese, 
asthma, and obese asthmatic animals were significantly decreased 
when compared to control animal (Group I, *p<0.05) and significantly 
increased when compared to disease control animal (Group II, III, and 
IV as @, #, and $ p<0.05) with leptin treatment. It was also observed that 
both parameters were worsening in treatment with leptin antagonist 
(Fig. 1).
Effect of leptin analog and antagonist on biochemical parameters
7 days administration of leptin analog in disease control groups revealed 
significant decrease in serum leptin level in obese and obese asthmatic 
group when compared to control (Group I, *p<0.05). It was observed 
that significantly increase in leptin-treated animals when compared 
to disease control animal (Group II, III, and IV as @, #, and $p<0.05) 
while significant decrease in leptin antagonist-treated animals when 
compared to disease control group.
Administration of leptin analog in disease control groups revealed 
significant increase in serum TNF-α level in obese and obese asthmatic 
group when compared to control (Group I, *p<0.05). It was observed 
that significantly decrease in leptin-treated animals when compared to 
disease control animal (Group II, III, and IV as @, #, and $p<0.05) while 
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no changes were observed with leptin antagonist-treated animals. 
Serum ghrelin level remains unchanged in all groups (Fig. 2).
DISCUSSION
Obesity is a disorder of inflammation and energy imbalance, occurring 
when calorie expenditure is less compared to high-caloric food 
intake [16]. Asthma symptoms such as dyspnea and wheezing appear as 
a result of excess of thoracic and abdominal fat deposition [17]. Despite 
complex etiological factors for both conditions, leptin resistance found 
to be one of the causes of asthmatic symptom in obesity [18]. In the 
present study, we evaluated role of leptin resistance in pathogenesis of 
asthma in obese condition and also focused on the effect of exogenous 
leptin and leptin antagonist in this comorbid condition.
Leptin, an adipokine hormone, inhibits food intake and increases 
energy expenditure by central action on hypothalamus [19,20] while 
ghrelin reported to be involved in increasing food intake [21]. Leptin 
effect is, therefore, antagonistic to the ghrelin effect. Previous studies 
of Rosická et al. reported that serum level of leptin and ghrelin was 
elevated in obesity [22]. This both hormone’s actions is due to their role 
of regulating energy homeostasis through the changes in neuropeptide 
Y secretion [23]. In our study, it was found that administration leptin 
analog reduced the body weight of animals while administration of 
leptin antagonist increased body weight of animals when compared to 
diseased control group at the 12th week. In same comparison, ghrelin 
levels were significantly higher. The reason for such elevation would be 
leptin resistance [18]. Previously, it was found that leptin resistance is 
one of the factors for pathogenesis of obesity [10] and now suggested 
to be involved in the development of asthma in obesity. Thus, we 
proposed that leptin resistance was accompanied by increased in 
serum ghrelin and serum leptin levels [22,23]. Clinical and preclinical 
studies suggested that obesity-induced raise in leptin level and leptin 
resistance would be responsible for worsening asthma symptoms [23].
We investigated changes in serum leptin, TNF-α, and ghrelin level 
in animals with obesity, asthma, and obese asthmatic condition after 
exogenous leptin analog and leptin antagonist. Leptin and TNF-α levels 
were significantly increased in obese animals and obese asthmatic 
animals when compared with normal control animals. It has been 
previously reported that leptin increases the level of inflammatory 
mediators such as TNF-α [23]. Furthermore, respiratory parameters 
tidal volume and airflow rate were significantly decreased in diseased 
control animals. Therefore, it may be suggested that leptin resistance 
aggravates the asthmatic condition.
In the present study, it was observed that leptin administration improve 
the state of leptin resistance as observed with reduction in body weight 
at the 12th week. Administration of leptin antagonist significantly 
decreases serum level of leptin. Hence, decrease in serum leptin level 
may be responsible for the development of asthma. Furthermore, 
elevated level of TNF- α in leptin antagonist treated group worsens the 
symptoms of asthma. It is well established that serum level of TNF-α was 
significantly reduced to produce anti-inflammatory action by treatment 
with leptin analogue [24,25]. Respiratory parameter was significantly 
increased in disease control animal when treated with exogenous leptin 
while leptin antagonist reduces respiratory parameter. Thus, leptin 
antagonist ultimately potentiates weight gain (due to blocking of leptin 
effect) and thereby worsen the state of asthma. Hence, we may conclude 
that leptin could be alternative treatment for resistant type of asthma.
CONCLUSION
From our study, we conclude that higher level of serum leptin may 
be involved in the development of leptin resistance and thus induce 
Table 1: Effect of leptin analog and antagonist on body weight
Groups (weeks) I II III IV V VI VII VIII IX X
1 22±0.32 20±0.14 24±0.34 21±0.34 23±0.64 21±0.14 23±0.21 24±0.36 22±0.09 23±0.64
2 24±0.54 26±0.29 24±0.20 22±0.28 24±0.36 24±0.38 23±0.15 28±0.26 24±0.20 22±0.28
3 25±0.53 30±0.16 25±0.15 26±0.36 31±0.26 31±0.21 31±0.11 32±0.17 31±0.29 31±0.21
4 31±0.14 45±0.58 29±0.78 45±0.74 41±1.70 33±0.46 43±0.43 37±0.86 28±0.46 42±0.43
5 34±0.28 54±0.82 32±0.17 53±1.29 44±2.00 41±0.29 48±0.75 40±0.75 31±0.82 50±0.75
6 36±0.20 53±0.82 38±0.17 53±0.85 48±1.15 40±0.14 55±0.79 41±0.88 31±0.82 46±0.71
7 38±0.13 54±0.79 41±0.11 54±0.99 54±1.05 41±0.09 56±0.72 42±0.74 31±0.66 49±0.79
8 39±0.13 55±0.55 41±0.25 56±0.90 59±0.81 42±0.14 58±0.65 42±0.53 32±0.60 52±0.61
9 38±0.46 56±1.05 42±0.43 59±0.91 61±1.49 41±0.45 59±0.86 47±0.86 39±0.45 57±0.86
10 36±0.48 57±0.86 41±0.43 60±0.46 59±1.15 41±0.45 60±0.91 53±0.43 39±0.45 55±0.68
11 35±0.34 58±0.91 42±0.43 59±0.82 49±2.13 30±0.33 51±1.23 59±0.97 45±0.96 58±0.43
12 35±0.14 59±0.63* 42±0.53 59±0.58* 30±0.68@ 18±0.38# 27±0.67$ 63±1.01 59±0.35 62±0.34
*p<0.05 when compared with Group-I. @p<0.05 when compared with Group-II. #p<0.05 when compared with Group-III. $p<0.05 when compared with Group-IV
Fig. 1: Effect of leptin analog and leptin antagonist on tidal volume and respiratory flow rate. *p<0.05 when compared with Group-I. 
@ p<0.05 when compared with Group-II. #p<0.05 when compared with Group-III. $p<0.05 when compared with Group-IV
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obesity and asthma. These comorbid conditions could be improved by 
leptin analog (by improving state of leptin resistance). However, further 
studies are needed to determine clinical efficacy of leptin analogs in 
patient of asthma-associated obesity. It is needed the effect of leptin 
analog with standard drugs of asthma and obesity.
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